HAMBURG, Germany—Evotec AG and AstraZeneca have signed an agreement to take joint action to combat kidney diseases. Initial focus of the alliance will be exploring compounds and targets with novel mechanisms that have disease-modifying potential for the treatment of chronic kidney disease. Under the terms of this license and collaboration agreement, AstraZeneca will receive access […]
↧